NOVAVAX INC NVAX

Latest FY: 2025 Healthcare Biotechnology
Market Price $9.31
Market Cap $1.53B
P/E Ratio 3.61
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑64.7% YoY
$1.12B
3-Yr CAGR: -17.2%
Net Income ↑334.8% YoY
$440.30M
Net Margin: 39.2%
Free Cash Flow ↓-149.4% YoY
-$250.19M
FCF Yield: -16.34%
EPS (Diluted) ↑309.8% YoY
$2.58
Basic: $2.72
Return on Equity Efficiency
N/A
ROA: 37.4%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NVAX)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $15.4M $-222.6M $-280.0M $-1.03 0.00% $-255.5M $-273.7M
FY 2017 $31.2M +103.1% $-137.3M $-183.8M +34.4% $-0.63 +38.8% 0.00% $-138.7M $-142.9M +47.8%
FY 2018 $34.3M +10.0% $-139.5M $-184.7M -0.5% $-0.50 +20.6% 0.00% $-184.8M $-186.2M -30.3%
FY 2019 $18.7M -45.6% $-86.2M $-132.7M +28.2% $-5.51 -1,002.0% 0.00% $-136.6M $-138.5M +25.6%
FY 2020 $475.6M +2,448.5% $460.5M $-418.3M -215.2% $-7.27 -31.9% 0.00% $-42.5M $-97.2M +29.8%
FY 2021 $1,146.3M +141.0% $1,125.2M $-1,743.8M -316.9% $-23.44 -222.4% 0.00% $322.9M $265.5M +373.2%
FY 2022 $1,981.9M +72.9% $1,079.2M $-657.9M +62.3% $-8.42 +64.1% 0.00% $-415.9M $-505.0M -290.2%
FY 2023 $983.7M -50.4% $639.9M $-545.1M +17.2% $-5.41 +35.7% 0.00% $-714.0M $-767.7M -52.0%
FY 2024 $682.2M -30.7% $479.4M $-187.5M +65.6% $-1.23 +77.3% 0.00% $-87.3M $-100.3M +86.9%
FY 2025 $1,123.5M +64.7% $1,050.4M $440.3M +334.8% $2.58 +309.8% 0.00% $-244.6M $-250.2M -149.4%
$

Valuation

Market Price $9.31
Market Cap $1.53B
Enterprise Value $1.29B
P/E Ratio 3.61
P/B Ratio N/A
FCF Yield -16.34%
Dividend Yield N/A
Shares Outstanding 164,438,100
%

Profitability & Margins

Gross Margin 93.50%
Operating Margin 40.30%
Net Margin 39.19%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) 37.42%
Asset Turnover 0.95x
Revenue 3-Yr CAGR -17.24%
🛡️

Financial Health & Liquidity

Current Ratio 2.13
Cash Ratio 0.52
Debt / Equity -0.000
Debt / Assets 0.000
Cash & Equivalents $240.63M
Total Debt N/A
Book Value / Share $-0.78
💧

Cash Flow Efficiency

Operating Cash Flow -$244.63M
Capital Expenditures (CapEx) $5.56M
Free Cash Flow -$250.19M
OCF / Revenue -21.77%
FCF / Revenue -22.27%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $2.58
EPS (Basic) $2.72
Dividends / Share N/A
Book Value / Share $-0.78
EPS YoY Growth 309.76%
🏛️

Balance Sheet (FY 2025)

Total Assets $1.18B
Total Liabilities $1.30B
Stockholders' Equity -$127.75M
Current Assets $978.28M
Current Liabilities $459.95M